Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

266
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
266
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

130
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
130
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adoption and Early Implementation Evaluation of a Heart Failure Nursing Protocol in Veterans Health Clinics.

Journal of nursing care quality·2026
Same author

Impact of the Veterans Affairs National Telestroke Program's Subacute Telestroke Service on Interhospital Transfers.

The Neurohospitalist·2025
Same author

Editorial: Using the RE-AIM framework and other implementation theories, models, and frameworks to guide the implementation and evaluation of rural health innovations.

Frontiers in health services·2025
Same author

Feasibility of Conducting Real-Time Qualitative Interviews With Emergency Department Patients: Lessons From Lung Cancer Screening Research.

Annals of emergency medicine·2025
Same author

Clinician Perspectives on Barriers and Facilitators to Providing Medications for Opioid Use Disorder for Adolescents.

Journal of addiction medicine·2025
Same author

Feasibility and acceptability of a telephone-based ACT intervention for caregivers (TACTICs) of adults with Alzheimer's disease and related dementias (ADRD): a randomized pilot during the COVID-19 pandemic.

Aging & mental health·2025

Related Experiment Video

Updated: Jul 11, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.6K

Pharmacogenomics implementation across multiple clinic settings: a qualitative evaluation.

Sarah A Shue1, Elizabeth Rowe2, Lauren A Bell2

  • 1VA HSR&D Center for Health Information & Communication, Roudebush VA Medical Center, Indianapolis, IN 46202, USA.

Pharmacogenomics
|November 17, 2023
PubMed
Summary
This summary is machine-generated.

Implementing pharmacogenomics (PGx) testing faces challenges like unclear payment and workflow issues. However, strong leadership and multidisciplinary teams can facilitate its successful adoption in clinical settings.

Keywords:
CFIRadoptionbarriersfacilitatorspharmacogenetic testing

More Related Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.2K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.9K

Related Experiment Videos

Last Updated: Jul 11, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.6K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.2K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.9K

Area of Science:

  • Clinical implementation science
  • Genomic medicine

Background:

  • Clinical adoption of pharmacogenomics (PGx) testing is crucial for personalized medicine.
  • Understanding implementation barriers and facilitators is key to advancing PGx use.

Purpose of the Study:

  • To identify and examine barriers and facilitators to the active implementation of a PGx program.
  • To gather insights from diverse contributors within an academic healthcare system.

Main Methods:

  • Qualitative interviews were conducted with 28 contributors involved in PGx implementation.
  • Participants included clinical providers and informatics specialists.

Main Results:

  • Key barriers identified include unclear payment mechanisms, decision support tool development, rigid workflows, and provider education.
  • A multidisciplinary implementation team and leadership support were recognized as significant facilitators.
  • Participants proposed strategies to address identified barriers and leverage facilitators.

Conclusions:

  • Real-world perceptions from implementation contributors offer a comprehensive framework for PGx implementation.
  • Findings can inform best-practice guidelines to enhance PGx adoption in healthcare systems.